Acid Sphingomyelinase Deficiency Type C-Pipeline Review, H1 2017

Acid Sphingomyelinase Deficiency Type C-Pipeline Review, H1 2017


  • Products Id :- GMDHC9239IDB
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Acid Sphingomyelinase Deficiency Type C-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acid Sphingomyelinase Deficiency Type C-Pipeline Review, H1 2017, provides an overview of the Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline landscape.

Niemann-Pick C disease is one of a group of lysosomal storage diseases that affect metabolism and that are caused by genetic mutations. It involves the accumulation of sphingolipids in cells throughout the body, particularly reticuloendothelial cells (the mononuclear phagocyte system). Symptoms include enlarged liver, brain damage, difficulty walking and swallowing, increased sensitivity to touch, difficulty speaking, loss of muscle tone, learning difficulties.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acid Sphingomyelinase Deficiency Type C-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Acid Sphingomyelinase Deficiency Type C (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acid Sphingomyelinase Deficiency Type C (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Overview

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Companies Involved in Therapeutics Development

CTD Holdings Inc

Merck & Co Inc

Okklo Life Sciences BV

Orphazyme ApS

Sucampo Pharmaceuticals Inc

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Drug Profiles

arimoclomol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bryostatin-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Delta-tocopherol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NPC1 for Niemann-Pick Type C1 Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPGCD-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MLSA-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit oxLDL for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OKL-1014-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OR-0005-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PERL-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RND-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Niemann-Pick Type C Disease and Atherosclerosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Niemann-Pick Type C Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Cholesterol for Niemann-Pick Type C Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Trappsol Cyclo-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vorinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTS-270-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Dormant Projects

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Product Development Milestones

Featured News & Press Releases

Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease

Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C

Feb 21, 2013: Orphazyme Receives Orphan Drug Designation For OR0005 In EU

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Pipeline by CTD Holdings Inc, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Pipeline by Merck & Co Inc, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Pipeline by Okklo Life Sciences BV, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Pipeline by Orphazyme ApS, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Pipeline by Sucampo Pharmaceuticals Inc, H1 2017

Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

CTD Holdings Inc, Merck & Co Inc, Okklo Life Sciences BV, Orphazyme ApS, Sucampo Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 129520
Site License
USD 4000 INR 259040
Corporate User License
USD 6000 INR 388560

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com